Substitute form 144	9A/PTO	A10	Compl te if Known		
	/	()	Application Number	09/525,797	
INFORMATION	DISCLOSURE	SEP 2	Filing Date	03/15/2000	
STATEMENT E	Y APPLICANT	47~ 4	First Named Inventor	Athanasius A. Anagnostou	•
	E	` ' 2000 'S	Group Art Unit	1642	
(use as many shee	ts as necessary)		Examiner Name	Susan Ungar	
Sheet 1	of	1800 - 10EY	Attorney Docket Number	5218-39B	
		CMARIS			

			U.S. PATE	NTS AND PATENT PUBLICATION	ONS	
Examiner Cite No. Initials*	U.S. Paten	Document	Name of Patentee or Applicant of Cited Document	Date of Publication of	Pages, Columns, Lines, Where Relevant Passages	
		Number	Kind Code (if known)	or Cited Document	Cited Document MM-DD-YYYY	or Relevant Figures Appear
		•				70
	 			= = = = = = = = = = = = = = = = = = = =		- C
	 					2000
	 					ECHO 25
	 					1 CA/2 520
	† †			· · · · · · · · · · · · · · · · · · ·		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
						1600
						1600/2900
						-60
	<u> 1</u>					

	_			FOREIGN	PATENT DOCUMENTS			
	Cite No.	Foreign Patent Document			Name of Patentee or	Date of Publication	Pages, Columns, Lines, Where Relevant	T
	NO.	Office	Number	Kind Code (if known)	Applicant of Cited Document	of Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	
- CN	1	JP	02 096535	A	Chugai Pharm Co Ltd	04/09/1990	Abstract	
		 				<u> </u>		
	 	-						ļ
	 	 			<u> </u>			

		OTHER NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	du
	-2	Communication with Supplementary European Search Report, EP 97 94 0974, July 15, 2002	Fle
SM	3	Bukowski et al., Phase IV evaluation of clinical outcomes of PROCRIT (Epoetin alfa) in anemic cancer patients receiving chemotherapy, Blood, Journal of the American Society of Hematology, Vol. 84, No. 10, Supp. 1, December 1994, p. 129A	
	4	Taylor et al., Effect of nifedipine on changes in fibrinogen and von Willebrand factor in haemodialysis patients treated with recombinant human erythropoietin, Blood Coagulation and Fibrinolysis: An International Journal in Haemostasis and Thrombosis, Vol. 6, No. 2, April 1995, pp. 100-104	
	5	Taylor et al., Effect of erythropoietin therapy and withdrawal on blood coagulation and fibrinolysis in hemodialysis patients, Kidney International, Vol. 44, No. 1, July 1993, pp. 182-190	
P	6	Reinhart, Shear-dependence of endothelial functions, Experientia, Vol. 50, No. 2, February 15, 1994, pp. 87-93	
	7	U.S. Patent Application Serial No. 09/525,808, filed March 15, 2000	Kel

	/	//		
Examiner Signature	1		Date Considered	
ACMARAINICO I III III	- 77			

*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.